Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study

Abstract

Clinical remission occurred more frequently in patients treated with rifaximin 400 mg 3 times daily but the difference was not significant in this pilot study. A larger trial would be required to determine if rifaximin is effective for the treatment of active pouchitis. Rifaximin was well tolerated.